Figure 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Key Points

• The treatment outcomes indicate stable disease in some patients while others experienced progressing disease.
• The study evaluates effects on solid tumors through a dose-escalation approach, focusing on patient responses.
• This phase I study emphasizes the safety and tolerability of basroparib, a novel tankyrase inhibitor, in treating advanced tumors.
• Patients were monitored over cycles, showing varied disease responses across the enrolled individuals.